News | Prostate Cancer | December 31, 2015

Leading HIFU Expert Begins U.S.-Based Program with Treatment of First Prostate Cancer Patients

Patients with prostate cancer are now being treated with minimally invasive, high intensity focused ultrasound (HIFU) therapy, following the October 2015 U.S. Food and Drug Administration (FDA) regulatory authorization for prostate tissue ablation with the Sonablate HIFU device. The leading U.S. HIFU expert, Vituro Health Medical Director Stephen Scionti, M.D., has begun U.S.-based HIFU procedures.

Scionti is the first partner physician of Vituro Health, a comprehensive prostate care provider that empowers men during all stages of life. Prior to the FDA clearance, Scionti had been involved in the treatment of approximately 1,000 patients over the last decade at the International HIFU Prostate Cancer Centers in the Caribbean and Mexico and as lead proctor for the FDA trials in the United States.

“Ten years ago, I saw HIFU as an incredible opportunity to improve the care of prostate cancer patients because the modalities we were using then had such significant limitations with significant side effects,” Scionti said. “I became an early adopter of HIFU because of the promise of an outpatient, non-invasive procedure where we could customize treatment to the patient through proper understanding of where the tumor was in their prostate.”

Scionti says HIFU offers an opportunity – in properly selected patients – to treat cancer with a much reduced side-effect profile that preserves quality of life, including less chance of urinary leakage and sexual issues, which are common results after a radical prostatectomy, the traditional treatment.

On Dec. 4, 2015, 61-year-old Graceville, Fla., resident Daniel Hazell was the first patient of Scionti’s to be treated with HIFU on American soil. While he did not have to travel to a foreign country for his HIFU procedure – he was prepared to do so prior to the FDA clearance.

“Dr. Scionti explains all available options, but HIFU sounded best to me because it targeted only the cancer cells and had a speedy recovery time,” Hazell said. “Scionti’s bedside manner also made me really comfortable; I knew I was in good hands. Most doctors don’t spend a lot of time with you, but he does.”

Hazell says that just hours after his procedure he was able to go out to dinner, and two days later, he is feeling good.

“The success of Mr. Hazell’s case is the result of many of years of hard work. His procedure went smoothly – it was typical of how my procedures go,” Scionti said. “A rapid return to normalcy is a major advantage with HIFU. Within a week, patients won’t even notice that they had a procedure done.”

Patients are not the only ones to directly benefit from Scionti’s experience. Scionti is directly involved in the training process for urologists interested in incorporating HIFU technology into their practices. He has proctored procedures of more than 80 urologists at Sonacare’s international centers of excellence and served as director of Clinical Education and Training for USHIFU and SonaCare Medical, the manufacturer of the Sonablate.

“With HIFU, you cannot shortcut training or experience, which is why Vituro Health guides partner physicians through the extensive training protocol that is required to master highly complex HIFU procedures,” Scionti said. “If you’re a patient and want the advantages of this non-invasive revolutionary technology, do your homework and find the best physician with the most HIFU experience that you can; good outcomes are obtained by skilled and highly experienced HIFU physicians.”

“Dr. Scionti honestly is the best in this field – he’s done more HIFU cases than anyone else in the country,” said Clete Walker, CEO of Vituro Health. “Vituro Health wanted to partner with the leading physician so we can educate our patients and physician partners because that’s the most important thing.”

“If people are willing to trust their prostate health to a new procedure, they want to trust it to someone who has the most experience with this revolutionary procedure. In my opinion, that is Dr. Scionti,” Walker said.

Scionti will perform ten more HIFU procedures in 2015 and has several already scheduled for early 2016.

For more information: www.viturohealth.com

 

Related Content

Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy
News | Artificial Intelligence | May 31, 2019
Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at...
Dynamic Digital Radiography Used to Assess Undifferentiated Dyspnea
News | Digital Radiography (DR) | May 29, 2019
A clinical study presented at the American Thoracic Society (ATS) 2019 annual meeting, May 17-22 in Dallas, described...
Leica Biosystems Receives FDA Clearance for Aperio AT2 DX Digital Pathology System
Technology | Digital Pathology | May 29, 2019
Leica Biosystems has received clearance from the U.S. Food and Drug Administration (FDA) to market its Aperio AT2 DX...
New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
News | Oncology Diagnostics | May 28, 2019
A new clinical study shows that Natera's Signatera test identified colorectal cancer recurrence up to 16.5 months...
Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...